preclinical and clinical trials

Show results for

Unknown (6357)
Genomics (249)
Transcriptomics (187)
Proteomics (36)
Other (9)
Clinical (4)
Methylation profiling (3)
Models (2)
Metabolomics (2)

Organisms

Homo sapiens (140)
Mus musculus (75)
Andropogon gerardi (25)
Bacteria (25)
Canis lupus familiaris (25)
Cnidaria (25)
Cricetulus griseus (25)
Eukaryota (25)
Fasciola (25)
Hepatitis B virus (25)
Human betaherpesvirus 5 (25)
Madurella mycetomatis (25)
Mesocricetus auratus (25)
Miscanthus x giganteus (25)
Mus musculus (25)
Mycobacterium tuberculosis (25)
Orthoflavivirus (25)
Panicum virgatum (25)
Platyhelminthes (25)
Pseudomonas aeruginosa AES-1R (25)
Rattus norvegicus (25)
Rattus rattus (25)
Rhodococcus jostii RHA1 (25)
Saccharomyces cerevisiae (25)
Rattus norvegicus (14)
Macaca fascicularis (5)
Macaca mulatta (3)
Canis lupus (1)
Sus scrofa (1)
Staphylococcus aureus (1)

Organisms

Homo sapiens (105)
Mus musculus (65)
Rattus norvegicus (9)
Macaca fascicularis (5)
Macaca mulatta (3)
Sus scrofa (1)

Repository

ENA (218)
geo (181)
biostudies-arrayexpress (40)
pride (25)
EGA (9)
MassIVE (8)
BioModels (2)
iProX (2)
MetaboLights (2)
PanoramaPublic (1)

Tissue

Cell culture (7)
Lung (3)
Type II pneumocyte (3)
Brain (2)
Epithelial cell (2)
Liver (2)
Blood cell (1)
Blood plasma (1)
Cell suspension culture (1)
Cervical epithelial cell (1)
Dendritic cell (1)
Parenchyma (1)
Pleural mesothelioma cell (1)
Stem cell (1)

Disease

Lung adenocarcinoma (4)
Cancer (2)
Colorectal Neoplasms (2)
Ascites (1)
Metastatic Extracranial Malignant Solid Neoplasm (1)
Brain cancer (1)
Brain glioblastoma multiforme (1)
Cervix carcinoma (1)
Idiopathic pulmonary fibrosis (1)
Malignant mesothelioma (1)
Spinal cord (1)

Technology Type

Mass Spectrometry (25)
Bottom-up proteomics (12)
Shotgun proteomics (7)
Affinity purification coupled with mass spectrometry proteomics (5)
Data-independent acquisition (3)
SWATH MS (2)
HiSeq X Ten, ILLUMINA, Illumina HiSeq 2500 (1)
NMR spectroscopy (1)
Mass spectrometry (1)
DiaPASEF (1)
HDMSE (1)
Top-down proteomics (1)

Instrument Platform

NextSeq 550 (2)
Orbitrap Exploris 480 (2)
NextSeq 500 (1)
6490 Triple Quadrupole LC/MS (1)
Agilent 6550 LC-MS/MS (1)
Exactive Plus (1)
LTQ Orbitrap Velos (1)
Orbitrap Astral (1)
Orbitrap Eclipse (1)
Orbitrap Fusion Lumos (1)
Q Exactive Plus (1)
TimsTOF fleX (1)
Nuclear Magnetic Resonance (NMR) - (1)
Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - reverse phase (1)

Publication Date

2025 (53)
2023 (38)
2024 (36)
2026 (31)
2012 (14)
2022 (13)
2021 (11)
2016 (10)
2020 (10)
2009 (7)
2013 (6)
2011 (6)
2018 (6)
2008 (5)
2014 (4)
2017 (4)
2010 (2)
2019 (2)
2015 (1)
2007 (1)

CHEBI ID

CHEBI:16761 (3)
CHEBI:17154 (2)
CHEBI:16946 (2)
CHEBI:18050 (2)
CHEBI:16027 (2)
CHEBI:15422 (2)
CHEBI:16467 (2)
CHEBI:71201 (1)
CHEBI:36559 (1)
CHEBI:16300 (1)
CHEBI:32544 (1)
CHEBI:16675 (1)
CHEBI:995 (1)
CHEBI:15763 (1)
CHEBI:15927 (1)
CHEBI:16171 (1)
CHEBI:18361 (1)
CHEBI:18344 (1)
CHEBI:16828 (1)
CHEBI:17380 (1)
CHEBI:30249 (1)
CHEBI:18304 (1)
CHEBI:16960 (1)
CHEBI:15379 (1)
CHEBI:17111 (1)
CHEBI:18009 (1)
CHEBI:16474 (1)
CHEBI:15846 (1)
CHEBI:16134 (1)
CHEBI:18367 (1)

Metabolite Name

2,5-di-tert-Butylhydroquinone (1)
Uridine 5'-diphosphoglucuronic acid (1)
D-Raffinose (1)
L-Glutathione oxidized (1)
L-Glutathione (reduced) (1)
Cyclic ADP-ribose (1)
AICA ribonucleotide (1)
N-Acetyl-1-aspartylglutamic acid (1)
Folic acid (1)
Cyclic AMP (1)
Inosinic acid (1)
Propan-2-one (1)
Methadyl Acetate (1)
3-Hydroxyisovaleric acid (1)
3R-hydroxy-butanoic acid (1)
Ethanol (1)
Isobutyric acid (1)
S-Lactoylglutathione (1)
Formic acid (1)
Adenosine triphosphate (1)
Guanosine triphosphate (1)
Dimethylamine (1)
Pyroglutamic acid (1)
L-Homoserine (1)
Acetamide (1)
Isopropyl alcohol (1)
Propylene glycol (1)
Propionic acid (1)
2-Hydroxy-3-methylpentanoic acid (1)
Acetoacetic acid (1)

First Public Date

2025 (48)
2023 (43)
2024 (35)
2026 (28)
2014 (16)
2022 (12)
2021 (11)
2020 (11)
2018 (5)
2017 (5)
2016 (2)
2019 (1)
2015 (1)

Modelling Approach

Differential equation model (1)
Ordinary differential equation model (1)

Study status

Not yet recruiting (2)
Not provided (1)
Completed (1)

Lab affiliation

Thoracic Oncology Molecular Medicine Program Moffitt Cancer Center Tampa, FL, USA (4)
Daglig leder, PROMEC Institutt for klinisk og molekylær medisin lars.hagen@ntnu.no 73598508 72573342 Laboratoriesenteret, 231.04.008, Øya, Erling Skjalgssons gate 1 (2)
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA (2)
1. Translational Immunology Research Program, Transplantation Laboratory, University of Helsinki, Helsinki, Finland. 2. HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland (1)
Biological Mass Spectrometry Lab Department of Translational Medicine (DiMeT) Center for Translational Research on Autoimmune & Allergic Diseases - CAAD University of Piemonte Orientale Corso Trieste 15/A, 28100, Novara, Italy (1)
Chemical Biology Laboratory, National Cancer Institute (1)
Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm 17177, Sweden. Department of Pharmacological & Technological Chemistry, I.M. Sechenov First Moscow State Medical University, Moscow 119146, Russia. (1)
Daglig leder, PROMEC Institutt for klinisk og molekylær medisin lars.hagen@ntnu.no 73598508 72573342 Laboratoriesenteret, 231.04.008, Øya, Erling Skjalgssons gate 1 PROMEC, Norway (1)
Department of Biochemistry & Molecular Biology, University of British Columbia, Vancouver, BC, Canada (1)
Functional Proteomics, ICR (1)
Georgetown University, USA (1)
Helmholtz diabetes center (1)
IRCCS Istituto G Gaslini (1)
Indiana University (1)
Institute of Lung Health and Immunity, and Comprehensive Pneumology Center with the CPC-M bioArchive, Ludwig-Maximilians-Universität München and Helmholtz Zentrum München, Munich, Germany, Member of the German Center for Lung Research (DZL); 8Department of Pediatrics, and Division of Pulmonary Sciences and Critical Care Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA (1)
Instituto de Neurociencias de Castilla y León (INCYL), Departamento de Bioquímica y Biología Molecular, Universidad de Salamanca, Spain (1)
NBE-DMPK Innovative BioAnalytics, Merck Serono RBM S.p.A., an affiliate of Merck KGaA, Darmstadt, Germany (1)
SQY Therapeutics, 2 Av. de la Source de la Bièvre, 78180 Montigny-le-Bretonneux, France Université de Versailles St- Quentin, U1179 INSERM, UFR des Sciences de la Santé - LIA BAHN CSM, France. (1)
TRIO Translational Research for Infectious Diseases and Oncology, Innere Med I, Uniklinik Köln, Köln (1)
Tsinghua University (1)

Keyword

Symptomatic malignant ascites due to advanced-stage gastrointestinal cancers (1)
Anti-IL-1α True Human antibody (1)
Trifluridine/tipiracil (1)
1st line (1)
Phase I/II (1)
Immune Checkpoint Inhibitors (1)
Zaltrap (1)
MCRC (1)
Aflibercept (1)
Trifluridine (1)
FOLFIRI (1)
Irinotecan (1)
Leucovorin (1)
Bevacizumab (1)
Fluorouracil (1)
Levoleucovorin (1)

IsPrivate

False (2)

Study type

Transcription profiling by array (34)
Interventional (4)
RNA-seq of coding RNA (3)
Genotyping by array (2)
MicroRNA profiling by high throughput sequencing (1)

Release Date

2022 (891)
2021 (884)
2023 (731)
2020 (605)
2025 (505)
2024 (428)
2019 (400)
2018 (366)
2016 (314)
2017 (311)
2015 (257)
2014 (202)
2013 (139)
2012 (110)
2011 (78)
2026 (64)
2010 (49)
2009 (26)
2008 (18)
2007 (7)
2006 (7)
2004 (4)
2005 (1)

Location

Greece (1)
China (1)
Germany (1)

Previous page
1 / 685
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 685
Next page

Sort by:

Relevance

Page size

Transcription profiling of human peripheral blood mononuclear cells treated with a CDK inhibitor

A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinic...

ORGANISM(S): Homo sapiens

2009-03-28 | E-GEOD-15389 | biostudies-arrayexpress

Preclinical efficacy of a live vesicular stomatitis virus-based Lassa virus vaccine candidate advanced for human clinical trials

PRJNA1031656 | ENA

Moving Forward in Cervical Cancer: Enhancing Susceptibility to DNA Repair Inhibition and Damage, an NCI Clinical Trials Planning Meeting Report.

Not available

S-EPMC7669233 | biostudies-literature

New considerations in the design of clinical trials for amyotrophic lateral sclerosis.

Not available

S-EPMC3335743 | biostudies-literature

Preclinical efficacy of a live vesicular stomatitis virus-based Lassa virus vaccine candidate advanced for human clinical trials

We advanced a promising experimental vaccine for immunizing against the Lassa virus surface glycoprotein as a candidate for human trials. Preclinical evaluation of the vaccine candidate based on a live vesicular stomatitis virus (VSV) vector showed that it was highly efficacious in cynomolgus macaqu...

ORGANISM(S): Macaca fascicularis

2024-11-30 | GSE246148 | GEO

Strategies for late phase preclinical and early clinical trials of senolytics.

Not available

S-EPMC8627448 | biostudies-literature

Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials.

Not available

S-EPMC10391091 | biostudies-literature

Recruiting to preclinical Alzheimer's disease clinical trials through registries.

Not available

S-EPMC5399544 | biostudies-literature

Science-Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical Labels.